The major objective of this proposal is to define a specific role for collagen degradation and tissue remodeling during angiogenesis. The investigator proposes to examine the functional significance of proteolytic modification of interstitial collagen type-I, a major component of the vascular extracellular matrix that has historically been considered as a structural component regulating tissue morphogenesis and stability. Angiogenesis has been suggested to depend on both cell adhesion and proteolytic mechanisms. However, to date, little is known concerning how cell adhesion receptors and proteolytically degraded extracellular matrix (ECM) components function cooperatively in the regulation of angiogenesis in vivo. The potential cellular and biochemical mechanisms by which proteolytically degraded collagen and resulting fragments can function as a ligand for vascular integrin alphav beta3, potentiating endothelial cell survival and angiogenesis will be examined. The hypothesis is that matrix metalloproteinases (MMPs), the primary class of enzymes capable of specifically degrading interstitial collagen, are up regulated and selectively associated with angiogenic blood vessels in vivo. It will be determined whether the elevated levels of MMPs are expressed in a proteolytically active form that could initiate the formation of proteolyzed interstitial collagen in the immediate microenvironment of angiogenic blood vessels. The ability of proteolytic degradation of collagen to reveal cryptic adhesive sequences that provide a physiologically important ligand for vascular integrin alphav beta3-mediated event necessary for the ligation of endothelial cell survival and angiogenesis will be tested. Since angio-genesis plays a critical role in a variety of normal and pathological processes, understanding the molecular events that regulate this process is of paramount importance, not only to our basic understanding of angiogenesis, but also to the design of novel strategies for the treatment of diseases characterized by neovascularization. Therefore, this study should provide new information to bridge the gap in our understanding of the complex mechanisms that regulate new blood vessels formation in vivo and provide the first evidence for a specific role for proteolyzed collagen in the regulation of endothelial cell survival and angiogenesis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29CA074132-03
Application #
2683708
Study Section
Pathology B Study Section (PTHB)
Program Officer
Mohla, Suresh
Project Start
1997-04-05
Project End
2002-03-31
Budget Start
1998-04-01
Budget End
1999-03-31
Support Year
3
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Southern California
Department
Biochemistry
Type
Schools of Medicine
DUNS #
041544081
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Hassanieh, Loubna; Rodriguez, Dorothy; Xu, Jinsong et al. (2003) Generation of a monoclonal antibody to a cryptic site common to both integrin beta1 as well as gelatinase MMP9. Hybrid Hybridomics 22:285-92
Hangai, Masanori; Kitaya, Norihiko; Xu, Jingsong et al. (2002) Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. Am J Pathol 161:1429-37
Brooks, Peter C; Roth, Jennifer M; Lymberis, Stella C et al. (2002) Ionizing radiation modulates the exposure of the HUIV26 cryptic epitope within collagen type IV during angiogenesis. Int J Radiat Oncol Biol Phys 54:1194-201
Stefansson, S; Petitclerc, E; Wong, M K et al. (2001) Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem 276:8135-41
McMahon, G A; Petitclerc, E; Stefansson, S et al. (2001) Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 276:33964-8
Xu, J; Rodriguez, D; Petitclerc, E et al. (2001) Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 154:1069-79
Petitclerc, E; Boutaud, A; Prestayko, A et al. (2000) New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J Biol Chem 275:8051-61
Xu, J; Rodriguez, D; Kim, J J et al. (2000) Generation of monoclonal antibodies to cryptic collagen sites by using subtractive immunization. Hybridoma 19:375-85
Petitclerc, E; von Schalscha, T; Brooks, P C (2000) The chimeric human/mouse model of angiogenesis. Methods Mol Biol 137:213-21
Petitclerc, E; Stromblad, S; von Schalscha, T L et al. (1999) Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res 59:2724-30